Moreover, it also demonstrated that positive VAP-1/TAM markers co-immunoreactivities yielded poorer prognosis for glioma patients (VAP-1/CD68, p < 0.0001; VAP-1/iNOS, p = 0.0113; VAP-1/CD163, p < 0.0001; Table 4). Here, CD68 is linked to central nervous system cancer.